ARVINAS, INC. (ARVN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
35/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseARVN / S&P -21.60% / 15.20% |
LoseARVN / S&P -15.05% / 15.00% |
LoseARVN / S&P -123.76% / 50.40% |
| 2026-Q11/3 |
LoseARVN / S&P -10.62% / -4.33% |
LoseARVN / S&P -79.06% / 11.30% |
WinARVN / S&P 381.82% / 27.70% |
| 2025-Q41/3 |
WinARVN / S&P 39.20% / 2.65% |
LoseARVN / S&P -0.30% / 9.00% |
LoseARVN / S&P -58.84% / 13.40% |
| 2025-Q32/3 |
WinARVN / S&P 15.76% / 8.12% |
WinARVN / S&P 93.85% / 4.61% |
LoseARVN / S&P -83.09% / 13.45% |
| 2025-Q21/3 |
LoseARVN / S&P 4.84% / 10.94% |
WinARVN / S&P 299.57% / 4.83% |
LoseARVN / S&P -80.91% / 10.63% |
| 2025-Q11/3 |
LoseARVN / S&P -63.38% / -4.27% |
WinARVN / S&P 498.74% / 4.98% |
LoseARVN / S&P -89.09% / 10.57% |
| 2024-Q41/3 |
LoseARVN / S&P -22.17% / 2.41% |
WinARVN / S&P 235.54% / 5.25% |
LoseARVN / S&P -58.16% / 6.15% |
| 2024-Q30/3 |
LoseARVN / S&P -7.48% / 5.89% |
LoseARVN / S&P 1.07% / 5.89% |
LoseARVN / S&P -13.22% / 6.11% |
| 2024-Q20/3 |
LoseARVN / S&P -35.51% / 4.28% |
LoseARVN / S&P -40.95% / 5.38% |
LoseARVN / S&P -5.20% / 5.12% |
| 2024-Q11/3 |
LoseARVN / S&P 0.29% / 10.56% |
LoseARVN / S&P -48.07% / 5.71% |
WinARVN / S&P 7.08% / 5.59% |
| 2023-Q42/3 |
WinARVN / S&P 109.57% / 11.69% |
LoseARVN / S&P -40.21% / 6.81% |
WinARVN / S&P 24.67% / 7.78% |
| 2023-Q32/3 |
LoseARVN / S&P -20.87% / -3.27% |
WinARVN / S&P 32.94% / 7.52% |
WinARVN / S&P 15.72% / -5.03% |
| 2023-Q22/3 |
LoseARVN / S&P -9.15% / 8.74% |
WinARVN / S&P 64.58% / 9.50% |
WinARVN / S&P 24.83% / -8.57% |
| 2023-Q12/3 |
LoseARVN / S&P -20.14% / 7.50% |
WinARVN / S&P 102.81% / 10.77% |
WinARVN / S&P 35.17% / -15.69% |
| 2022-Q42/3 |
LoseARVN / S&P -23.11% / 7.56% |
WinARVN / S&P 181.16% / 11.88% |
WinARVN / S&P 39.01% / -17.99% |
| 2022-Q32/3 |
WinARVN / S&P 5.70% / -4.88% |
WinARVN / S&P 430.53% / 13.47% |
LoseARVN / S&P ARVN unavailable / -1.41% |
| 2022-Q21/3 |
LoseARVN / S&P -37.46% / -16.10% |
WinARVN / S&P 359.40% / 13.71% |
LoseARVN / S&P ARVN unavailable / 11.04% |
| 2022-Q11/3 |
LoseARVN / S&P -18.07% / -4.60% |
WinARVN / S&P 220.18% / 15.97% |
LoseARVN / S&P ARVN unavailable / 42.23% |
| 2021-Q41/3 |
LoseARVN / S&P -0.05% / 11.03% |
WinARVN / S&P 113.78% / 15.00% |
LoseARVN / S&P ARVN unavailable / 96.40% |
| 2021-Q31/3 |
WinARVN / S&P 6.73% / 0.58% |
LoseARVN / S&P -7.55% / 10.77% |
LoseARVN / S&P ARVN unavailable / 69.42% |
| 2021-Q21/3 |
WinARVN / S&P 16.49% / 8.55% |
LoseARVN / S&P -55.44% / 6.58% |
LoseARVN / S&P ARVN unavailable / 51.81% |
| 2021-Q10/3 |
LoseARVN / S&P -22.17% / 6.17% |
LoseARVN / S&P -53.19% / -1.06% |
LoseARVN / S&P ARVN unavailable / 7.39% |
| 2020-Q41/3 |
WinARVN / S&P 259.72% / 12.15% |
LoseARVN / S&P -49.16% / -3.72% |
LoseARVN / S&P ARVN unavailable / -33.42% |
| 2020-Q30/3 |
LoseARVN / S&P -29.61% / 8.93% |
LoseARVN / S&P -41.05% / -2.04% |
LoseARVN / S&P ARVN unavailable / -27.10% |
| 2020-Q21/3 |
LoseARVN / S&P -16.77% / 20.54% |
WinARVN / S&P 217.05% / -0.46% |
LoseARVN / S&P ARVN unavailable / -27.11% |
| 2020-Q12/3 |
WinARVN / S&P -1.92% / -19.60% |
WinARVN / S&P 218.63% / 3.47% |
LoseARVN / S&P ARVN unavailable / -14.75% |
| 2019-Q42/3 |
WinARVN / S&P 90.67% / 9.07% |
WinARVN / S&P 200.81% / 5.36% |
LoseARVN / S&P ARVN unavailable / 2.99% |
| 2019-Q31/3 |
LoseARVN / S&P -2.00% / 1.70% |
WinARVN / S&P 208.16% / 5.02% |
LoseARVN / S&P ARVN unavailable / 0.21% |
| 2019-Q22/3 |
WinARVN / S&P 48.98% / 4.30% |
WinARVN / S&P 25.89% / 6.64% |
LoseARVN / S&P ARVN unavailable / 8.65% |
| 2019-Q11/3 |
WinARVN / S&P 14.86% / 13.65% |
LoseARVN / S&P ARVN unavailable / 8.12% |
LoseARVN / S&P ARVN unavailable / 14.29% |
| 2018-Q40/3 |
LoseARVN / S&P -23.83% / -13.52% |
LoseARVN / S&P ARVN unavailable / 9.05% |
LoseARVN / S&P ARVN unavailable / 18.23% |
| 2018-Q30/3 |
LoseARVN / S&P ARVN unavailable / 7.71% |
LoseARVN / S&P ARVN unavailable / 10.21% |
LoseARVN / S&P ARVN unavailable / 19.06% |
| 2018-Q20/3 |
LoseARVN / S&P ARVN unavailable / 3.43% |
LoseARVN / S&P ARVN unavailable / 9.03% |
LoseARVN / S&P ARVN unavailable / 14.46% |
| 2018-Q10/3 |
LoseARVN / S&P ARVN unavailable / -0.76% |
LoseARVN / S&P ARVN unavailable / 7.68% |
LoseARVN / S&P ARVN unavailable / 12.46% |
| 2017-Q40/3 |
LoseARVN / S&P ARVN unavailable / 6.64% |
LoseARVN / S&P ARVN unavailable / 7.03% |
LoseARVN / S&P ARVN unavailable / 13.82% |
| 2017-Q30/3 |
LoseARVN / S&P ARVN unavailable / 4.48% |
LoseARVN / S&P ARVN unavailable / 5.68% |
LoseARVN / S&P ARVN unavailable / 17.57% |
| 2017-Q20/3 |
LoseARVN / S&P ARVN unavailable / 3.09% |
LoseARVN / S&P ARVN unavailable / 4.83% |
LoseARVN / S&P ARVN unavailable / 17.74% |
| 2017-Q10/3 |
LoseARVN / S&P ARVN unavailable / 6.07% |
LoseARVN / S&P ARVN unavailable / 3.67% |
LoseARVN / S&P ARVN unavailable / 13.32% |
| 2016-Q40/3 |
LoseARVN / S&P ARVN unavailable / 3.82% |
LoseARVN / S&P ARVN unavailable / 2.09% |
LoseARVN / S&P ARVN unavailable / 7.05% |
| 2016-Q30/3 |
LoseARVN / S&P ARVN unavailable / 3.85% |
LoseARVN / S&P ARVN unavailable / 0.20% |
LoseARVN / S&P ARVN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ARVN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 19.53% | 20.78% |
| Annualized return | 19.53% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ARVN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.17% | 83.14% |
| Annualized return | -35.89% | 12.86% |
10Y · 2018-09-27 to 2026-08-27
| Metric | ARVN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -42.43% | 319.30% |
| Annualized return | -5.37% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |